Noxopharm signed a strategic MoU with Tezcat Biosciences, published major Sofra RNA research, and appointed Dr Olivier Laczka as CEO, while reporting positive safety data from its HERACLES trial and improving cash flow.
- MoU with Tezcat Biosciences to explore targeted drug delivery
- Sofra RNA platform featured in Nature Immunology journal
- Dr Olivier Laczka appointed CEO to drive Sofra development
- HERACLES trial dosing completed with positive safety results
- Cash position strengthened by A$2.8M R&D tax rebate and positive operating cash flow
Strategic Partnership Targets Cancer and Inflammation
Noxopharm Limited (ASX:NOX) has deepened its collaboration with US biotech Tezcat Biosciences by signing a Memorandum of Understanding (MoU) this quarter. The agreement builds on their existing partnership and aims to combine Noxopharm’s Sofra™ RNA therapeutics with Tezcat’s innovative drug delivery system, which targets immune and cancer cells precisely. This approach could open new avenues in treating cancer and chronic inflammatory diseases by enhancing drug payload delivery to specific diseased cells.
Sofra Platform Gains Scientific Validation
Leadership Transition Focused on Sofra Growth
In a leadership shake-up, Noxopharm appointed Dr Olivier Laczka as CEO following the resignation of Dr Gisela Mautner. Dr Laczka, previously Chief Scientific Officer, has been instrumental in developing the Sofra platform. His promotion signals a strategic focus on accelerating Sofra’s clinical and commercial progress. This move aligns with recent positive developments, including the completion of dosing in the HERACLES trial and the high-profile Sofra publication. Dr Laczka’s appointment was covered in detail earlier this month, highlighting the company’s intent to capitalise on its scientific momentum and market opportunities in autoimmune and oncology sectors.
Clinical Progress in Autoimmune Skin Disease
The HERACLES trial, testing SOF-SKN™ for cutaneous lupus erythematosus (CLE), wrapped dosing in December 2025 with encouraging safety and tolerability across all dose levels. Statistical analyses are underway, with results slated for presentation at the Australian Society for Clinical Immunology and Allergy (ASCIA) conference in September 2026. SOF-SKN™ targets a sizeable global market exceeding US$3.3 billion, initially focusing on CLE before potential expansion into psoriasis and dermatomyositis. The Sofra platform’s broader applicability to autoimmune diseases like rheumatoid arthritis and diabetes positions Noxopharm well within a growing therapeutic landscape.
Improved Cash Flow and Funding Vigilance
Financially, Noxopharm ended the quarter with A$952,000 in cash, bolstered by a A$2.8 million research and development tax rebate received in February. The company reported a positive net cash inflow from operating activities of A$848,000 for the quarter, a marked turnaround from the previous quarter’s outflows. However, research and development expenses increased to A$795,000, reflecting intensified activity. Noxopharm continues to manage its cash prudently while exploring various options to secure additional funding, mindful of market conditions and potential short-term catalysts. Convertible notes and a $5 million market subscription facility provide some financial flexibility as the company advances its pipeline.
Engagement Beyond the Lab
Beyond core R&D, Noxopharm demonstrated community engagement by attending the launch of the My Pain Assessment Communication Tool (MPaCT) in Canberra. This patient-led initiative aims to improve pain communication and management, reflecting Noxopharm’s broader commitment to supporting patients with autoimmune and inflammatory conditions. Such involvement complements its scientific endeavours and positions the company as a stakeholder in patient advocacy.
With the Sofra platform gaining scientific credibility and clinical validation, and a new CEO poised to drive growth, Noxopharm is navigating a critical phase. The coming months will be pivotal as the company prepares to unveil HERACLES trial data and explores the commercial potential of its collaborations and technologies.
Bottom Line?
Noxopharm’s strengthened leadership and collaborations set the stage for key clinical readouts and funding decisions in the coming months.
Questions in the middle?
- How will the HERACLES trial data shape Sofra’s clinical and commercial trajectory?
- What funding strategies will Noxopharm pursue to sustain its expanding R&D activities?
- How might the collaboration with Tezcat Biosciences accelerate Sofra’s drug delivery capabilities?